Pacific Biosciences Of California (PACB) Interest Coverage Ratio Growth (3y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -7.80% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | - |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -1.00% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 12.94% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -35.05% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 9.28% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | -4.98% |
| 10 | Pacific Biosciences Of California | 481.66 Mn | 205.70 Mn | 12.84 Mn | 42.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42.40% |
| Dec 31, 2025 | 0.27% |
| Sep 30, 2025 | -3.16% |
| Jun 30, 2025 | -11.81% |
| Mar 31, 2025 | -127.51% |
| Dec 31, 2024 | -44.00% |
| Jun 30, 2024 | -68.01% |
| Mar 31, 2024 | -6.50% |
| Mar 31, 2023 | 41.02% |
| Dec 31, 2022 | 3.33% |
| Sep 30, 2022 | 21.65% |
| Jun 30, 2022 | 21.28% |
| Mar 31, 2022 | 24.24% |
| Dec 31, 2021 | 27.49% |
| Jun 30, 2021 | 33.97% |
| Mar 31, 2021 | 22.97% |
| Mar 31, 2020 | -63.94% |
| Dec 31, 2019 | -7.45% |
| Sep 30, 2019 | -27.59% |
| Jun 30, 2019 | -18.54% |
| Mar 31, 2019 | -26.48% |
| Dec 31, 2018 | -228.64% |
| Sep 30, 2018 | -137.24% |
| Jun 30, 2018 | -31.79% |
| Mar 31, 2018 | -14.13% |
| Dec 31, 2017 | -10.05% |
| Sep 30, 2017 | -42.60% |
| Jun 30, 2017 | -4.18% |
| Mar 31, 2017 | -1.49% |
| Dec 31, 2016 | 4.60% |
| Sep 30, 2016 | 11.15% |
| Jun 30, 2016 | 8.54% |
| Mar 31, 2016 | 21.02% |
| Dec 31, 2015 | 83.81% |
| Sep 30, 2015 | 26.21% |
| Jun 30, 2015 | 63.51% |